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ABSTRACT
Objective: To compare the outcome and cost-effective-
ness of various forms of preoperative endometrial prepa-
ration prior to hysteroscopic endometrial destruction for
abnormal uterine bleeding.
Methods: This was a multicenter, prospective, compara-
tive, randomized study conducted in a tertiary care hos-
pital in Cairo, Egypt and 2 academic tertiary care teach-
ing hospitals in the United States. One hundred thirty-
one premenopausal women, who had completed child-
bearing, mean age of 45.7 years, with abnormal uterine
bleeding refractory to medical management without his-
tologic evidence of endometrial neoplasia were studied.
The 131 patients were randomized for preoperative
preparation for hysteroscopic endometrial destruction
into 1 of 5 groups as follows: Group I, dilation and curet-
tage (D & C) (39); Group II, gonadotropin-releasing hor-
mone analogue (GnRHa) for 1 month (23); Group III,
GnRHa for 3 months (26); Group IV, danazol for 3
months (26); and Group V, medroxyprogesterone acetate
(MPA) 15 mg for 3 months (27). The choice of endome-
trial ablation or endometrial resection was left to the sur-
geon.
Results: Improvement in bleeding patterns, amenorrhea,
operative times, complications, and relative cost were the
measured outcomes. The mean follow-up time was 1
year from the time of the procedure. Overall, in Group I,
39/39 (100%) improved and 7/39 (18.0%) experienced
amenorrhea; in Group II, 21/23 (91.3%) improved and
9/23 (39.1%) experienced amenorrhea; in Group III,
24/26 (92.3%) improved and 10/26 (38.5%) experienced
amenorrhea; in Group IV, 24/26 (92.3%) improved and
9/26 (34.6%) experienced amenorrhea; and in Group V,
INTRODUCTION
Gynecologists are called on frequently to treat menstrua-
tion disorders. When neoplastic conditions have safely
been ruled out and the patient has failed medical man-
agement and has completed childbearing, hysteroscopic
endometrial destruction is a viable, minimally invasive
and cost-effective treatment option that can often avoid
a more costly and potentially more complicated hys-
terectomy.1,2 Various pretreatment regimens have been
attempted to arrest endometrial growth and reduce vas-
cularity, which are believed to enhance the success of
the procedure.3,4 With greater demands being placed on
clinicians for cost-effective outcome-based treatment, it is
imperative to find the most efficient regimen for treating
women with this disorder. 
We evaluated the outcome of operative hysteroscopic
endometrial destruction in patients with abnormal uter-
ine bleeding who were ruled out for neoplastic condi-
tions and had failed medical management, and who were
randomized to various pretreatment protocols including
dilation and curettage (D & C), gonadotropin-releasing
hormone analogue (GnRHa), danazol, and depot
medroxyprogesterone acetate (MPA) before the operative
event.
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23/27 (85.1%) improved and 7/27 (25.9%) experienced
amenorrhea. 
Conclusion: Endometrial destruction whether by the
ablation or resection technique, regardless of the type of
surgical pretreatment is a safe and effective surgical
approach for treating abnormal uterine bleeding. D & C
or MPA appear to be the most cost-effective pretreatment
regimens. MPA pretreatment may confer the added
advantage of decreasing blood flow and allowing better
hysteroscopic visualization than D & C pretreatment.
Key Words: Hysteroscopy, Endometrial ablation,
Abnormal uterine bleeding.
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METHODS
This was a prospective, randomized, comparative investi-
gation conducted at 3 academic teaching hospitals. One
hundred thirty-one patients were enrolled in the study.
The mean age of the patients was 45.7 years. All study
patients had abnormal uterine bleeding refractory to
medical management, underwent endometrial sampling
to rule out neoplasia, and no longer desired to have chil-
dren. Patients underwent thoughtful counseling with
regard to future childbearing and contraceptive choices
prior to enrolling in the study. Other criteria followed
prior to endometrial destruction included the following:
degree of abnormal uterine bleeding at a level that justi-
fied hysterectomy, uterine size < 12 weeks, and patient
refusal of continued medical attempts to control bleeding. 
Patients were randomized into 1 of 5 pretreatment groups
before hysteroscopic endometrial destruction:
• Group I: D & C immediately before procedure.
• Group II: GnRHa, goserelin 3.6 mg SC, for 1 
month before procedure.
• Group III: GnRHa, goserelin 3.6 mg SC monthly, 
for 3 months before procedure.
• Group IV: danazol 400-600 mg PO per day, for 3 
months before procedure.
• Group V: MPA 15 mg PO per day, before 
procedure.
Informed consent was obtained from all patients, which
explained the involved side effects, risks, and benefits of
medications and the procedures. Alternative treatment
options were given to patients.
All surgical procedures were performed in the ambulato-
ry care unit, and the main outcome measures included
improvement in bleeding problem, amenorrhea, opera-
tive time, complications, and relative costs.
Endometrial destruction was carried out by either the
ablative technique with the 3.5-mm rollerball or by the
resection technique with a 24-French cutting loop.
Resection was performed with a Martin electro-diathermy
unit on a blended cutting coagulation current of 70 W.
The type of destruction was dependent upon the sur-
geon’s preference; however, the surgeons were consistent
with the type of technique used. We used Karl Storz hys-
teromat to push Glycine 1.5 fluid as a distension medium.
The pressure of the apparatus is between 60 to 90 mm
Hg. All procedures were carried out with a 26-French
continuous flow resectoscope, fitted with a 4-mm 25-
degree telescope. 
Patient follow-up was for 1 year after the procedure for
bleeding patterns. The patient reported the number of
pad changes during menses and subjective assessment of
the amount of menstrual blood loss. Complete blood
count was analyzed at follow-up also.
RESULTS
The measured clinical outcomes were defined as
improvement or amenorrhea. Improvement was defined
as a bleeding pattern that was acceptable to the patient
and clearly represented diminished menstrual flow com-
pared with that prior to treatment. Amenorrhea was
defined as no bleeding for a period ≥ 3 menstrual cycles.
Improvement was observed in 100% of the D & C pre-
treatment group, 91.3% of the GnRHa for 1 month pre-
treatment group, 92.3% of the GnRHa for 3 months pre-
treatment group, 92.3% of the danazol pretreatment
group, and 85.1% of the MPA pretreatment group. No sta-
tistically significant difference existed among groups with
regard to improvement status per chi-square analysis (P
= 0.99) (Table 1).
Amenorrhea was observed in 18% of the D & C pretreat-
ment group, 39.1% of the GnRHa for 1 month pretreat-
ment group, 38.5% of the GnRHa for 3 months pretreat-
ment group, 34.6% of the danazol pretreatment group,
and 25.9% of the MPA pretreatment group. No statistical-
ly significant difference existed among groups with
regard to amenorrhea per chi-square analysis (P = 0.59)
(Table 1).
To compare the techniques of hysteroscopic endometri-
al resection versus ablation, the outcomes between the D
& C and GnRHa for 3 months pretreatment groups was
made. One hundred per cent of resection patients versus
75.8% of ablation patients experienced improvement in
the D & C pretreatment group reflecting no significant
difference on chi-square analysis (P = 0.79). Ninety-three
percent of resection patients versus 90.9% of ablation
patients experienced improvement in the GnRHa for 3
months pretreatment group showing no significant dif-
ference on chi-square analysis (P = 0.80). Amenorrhea
was experienced by 30% of the resection patients under-
going D & C pretreatment versus 13.8% of ablation
patients in this same group representing no significantdifference on chi-square analysis (P = 0.63). Amenorrhea
was experienced by 33.3% of GnRHa for 3 months pre-
treatment who underwent resection versus 45.4% of this
group undergoing ablation with no significant difference
shown with Fisher’s exact test (P = 0.48) (Table 2).
Associated operative factors including operative time,
complications and relative costs among the various pre-
treatment groups were also studied. Operative times
were 68 ± 7, 39 ± 7, 37 ± 5, 43 ± 3, and 54 ± 9 minutes
for the D & C, GnRHa for 1 month, GnRHa for 3 months,
danazol, and MPA pretreatment groups, respectively.
Operative times were significantly longer for the D & C
and MPA groups compared with that of the other groups,
but were not significantly different from each other on
analysis of variance with the Ducan multiple range test,
P < 0.05. The only complication among our patients was
1 case of fluid overload that was successfully and easily
treated with diuretics and observation. The cost of the
various pretreatments (excluding procedure fees) in
decreasing order was GnRHa for 3 months which is
greater than the cost of danazol for 3 months which is
greater than the cost of GnRHa for 1 month which is
greater than the cost of MPA which is greater than the
cost of D & C pretreatment groups.
CONCLUSION
Endometrial ablation-resection is a safe and effective
means of controlling abnormal uterine bleeding (AUB)
refractory to medical management.5-7 This study demon-
strates many points of interest that can facilitate clinical
decision-making in the surgical management of AUB
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refractory to medical management. At a time when cost-
effectiveness of surgical procedures is paramount, it is
imperative to scrutinize treatment outcomes, cost, opera-
tive times, and complications to select the most appro-
priate and efficacious management for patients.
The overall premise of this study shows no significant
difference with regard to improvement or amenorrhea
based on various pretreatments prior to endometrial
destruction including D & C, GnRHa, danazol, or MPA.
This is consistent with the findings of Seeras and
Gilliland,8 who reported a trend but not a significant dif-
ference between the preoperative use of GnRHa or dana-
zol, and between ablation versus resection of the
endometrium.8 Maia et al9 achieved amenorrhea in 50%
of patients with no preoperative pretreatment before
endometrial resection in a series of 70 patients with men-
orrhagia. Conversely, however Sorensen et al10 found an
increased rate of amenorrhea at 1 year in the GnRHa pre-
treatment group compared with no pretreatment for
endometrial resection. Fraser et al11 compared GnRHa
and danazol before endometrial ablation and showed a
similar effect with 74% of GnRHa users and 62% of dana-
zol users achieving amenorrhea after 6 months of follow-
up. The strength of our study is based on the compari-
son of a wide array of hysteroscopic pretreatment.
For the purpose of the study, improvement included
both diminished menstrual flow and amenorrhea over
the measured follow-up period of 1 year. Our patients
achieved excellent improvement rates of 85.1% to 92.3%
regardless of the type of pretreatment used. These results
are consistent with the results reported by others.12
Table 1.
Outcome among 5 groups with various
pretreatments to endometrial destruction
Group (n) Improvement (%) Amenorrhea (%)
I (39) 39 (100) 7 (18)
II (23) 21 (91.3) 9 (39.1)
III (26) 24 (92.3) 10 (38.5)
IV (26) 24 (92.3) 9 (34.6)
V (17) 23 (85.1) 7 (25.9)
P-value NS* NS*
*comparison between any group by chi-square with Yates
correction
Table 2.
Comparison of D & C and 3 months of
GnRHa prior to endometrial destruction
Outcome
Improvement Amenorrhea
Technique Group I Group III Group I Group III
Resection 10/10 (100) 14/15 (93.3) 3/10 (30) 5/15 (33.3)
Ablation 22/29 (75.8) 10.11 (90.9) 4/29 (13.8) 5/11 (45.4)
P-value NS* NS* NS* NS†
*chi-square with Yates correction
†Fisher’s exact testHysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized,
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Although the rate of amenorrhea in our study was rela-
tively low (18% to 39.1%) when compared with that in
other studies (50% to 74%), our follow-up interval was
measured up to 1 year after surgery, whereas the studies
demonstrating higher rates of amenorrhea were followed
for the considerably less time of 2 to 6 months.9,11 We and
others believe that longer follow-up periods may yield
greater recurrence rates of bleeding, which may require
reoperation.12 
We found no statistically significant difference in the out-
come after endometrial resection versus ablation (Table
2). Others have reported similar rates when resection or
ablation techniques are used.8 The similar outcomes
demonstrated by resection and ablation suggest that the
surgeon should use the technique that best fits his or her
training and skill.
Operative times were measurably longer in the D & C
and MPA pretreatment groups compared with those in
the GnRHa and danazol groups. In the case of D & C pre-
treatment, the added time is accounted for by the time
required to set up and perform the D & C procedure prior
to endometrial destruction. The MPA pretreatment group
also required a longer time due to greater endometrial
thickness in some patients requiring repetitive destruction
and instrument cleaning. Operative times were consistent
with times reported by others (Table 3).10
Complications were fortunately rare in our study. Only 1
case of fluid overload was experienced, and it was easi-
ly dealt with through diuresis and observation.
Cost is an important factor in any treatment. Cost analy-
sis must also demonstrate acceptable quality for the treat-
ment in question. Although reduced hospital costs and
shorter recovery periods have been realized by using
endometrial destructive techniques versus hysterectomy,
definitive treatment of AUB favors hysterectomy. Among
the hysteroscopic endometrial destruction groups, vari-
ous pretreatments will greatly affect the overall cost. The
most costly pretreatments included the use of GnRHa for
3 months prior to the surgical procedure followed by
danazol pretreatment for 3 months, GnRHa for 1 month,
D & C, and MPA.
In conclusion, endometrial destruction whether performed
with the ablation or resection technique is a safe, effective
means to surgically control AUB.5 Surgeon preference
should dictate which procedure is used. Our study demon-
strated no significant difference in outcome regardless of
the type of pretreatment used. In this regard, the authors
recommend the most cost-effective pretreatment prior to
the surgical procedure, which includes either D & C or
MPA for 3 months Medroxyprogesterone acetate confers
the added advantage of controlling bleeding and induction
of an endometrial atrophying effect on the endometrium,
thus giving the surgeon better visualization for the proce-
dure.
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